Langerhans cells (LCs) are dendritic cells (DCs) localized in stratified epithelia, such as those overlaying skin, buccal mucosa, and vagina. The contribution of LCs to the promotion or control of immunity initiated at epithelial sites remains debated. We report in this paper that an immunogen comprising OVA linked to the B subunit of cholera toxin, used as delivery vector, was efficient to generate CTLs after vaginal immunization. Using Lang-EGFP mice, we evaluated the contribution of distinct DC subsets to the generation of CD4 and CD8 T cell responses. We demonstrate that the vaginal epithelium, unlike the skin epidermis, includes a minor population of LCs and a major subset of langerin 2 DCs. Intravaginally administered Ag is taken up by LCs and langerin 2 DCs and carried up to draining lymph nodes, where both subsets prime CD8 T cells, unlike blood-derived DCs, although with distinct capabilities. LCs prime CD8 T cells with a cytokine profile dominated by IL-17, whereas Lang 2 DCs induce IFN-g-producing T cells. Using Lang-DTR-EGFP mice to ensure a transient ablation of LCs, we found that these cells not only are dispensable for the generation of genital CTL responses but also downregulate these responses, by a mechanism that may involve IL-10 and IL-17 cytokines. This finding has implications for the development of mucosal vaccines and immunotherapeutic strategies designed for the targeting of DCs.
T he genital mucosa constitutes the major site of sexually transmitted infections. This mucosa is a highly specialized immune system including effector mechanisms, such as secretory Ab production and T cell responses, playing a crucial role in protection against pathogen invasion (1, 2) . Following genital exposure to HIV, the expression of secretory Abs and CTL responses in the genital compartment seems to be involved in the control of HIV infection by female sex-workers (3) (4) (5) .
In addition, it has been demonstrated that mucosal routes of immunization (nasal, genital) are more efficient than parenteral vaccination for inducing secretory Abs in genital tissues (6, 7) .
Moreover, genital immunization with subunit vaccines induces the generation of CTLs in draining ileosacral lymph nodes (ILNs) (8, 9) as well as in genital mucosa, whereas systemic immunization is unable to evoke vaginal CTL responses (9) . Nevertheless, a better understanding of the early events involved in the generation of CTLs initiated in the reproductive tract is required for the development of targeted vaccination strategies.
An effective cellular immune response requires that APCs process Ags and present epitopes to T cells. Dendritic cells (DCs) are known to be the most potent APCs able to prime both CD4 + and CD8 + T cells. In the immature stage, DCs act as sentinels, as they are located in most nonlymphoid tissues and in close contact with the epithelial surfaces, where they can sense and sample incoming pathogens. Among these, Langerhans cells (LCs) represent the immature DCs located in stratified epithelia, such as the skin and the buccal and vaginal mucosae. Because of their strategic location, LCs are thought to participate in maintaining peripheral tolerance and/or in sensing "danger" signals at epithelial surfaces (10) . The implication of LCs in the priming of CD8 T cells after vaginal immunization still remains to be determined. To date, few studies have analyzed the DC subsets located in the mouse vaginal mucosa. Parr and Parr (11) have highlighted the heterogeneity of APCs, including DCs, in the vaginal mucosa. Different subsets of DCs within the vaginal epithelium have been described on the basis of their differential expression of CD205 and F4/80. Their frequency and exact location in the epithelium and vaginal stroma were dependent on the menstrual cycle (11) . Iwasaki et al. (12, 13) have confirmed the heterogeneity of vaginal epithelial DCs (VEDCs) and have reported that VEDCs express very low levels or no langerin, a C-type lectin originally identified as a specific marker of LCs (14, 15) . Recently, Langerin + DCs have been also described in the mouse dermis (16) (17) (18) . Furthermore, knock-in mice that express the enhanced GFP (EGFP) and the receptor for diphtheria toxin under the control of the langerin gene have been engineered to study langerin + DC functions in vivo (19) (20) (21) . These mice *Institut National de la Santé et de la Recherche Médicale U634, Faculté de Méde-cine Pasteur;
constitute a unique tool to examine the frequency and functions of murine LCs in most stratified tissues. We have previously shown that the nontoxic B subunit of cholera toxin (CTB) constitutes an efficient delivery vector for inducing vaginal CTL responses against a colinked Ag after intravaginal immunization (9) . In this paper, we have reported the contribution of vagina-derived DCs, including LCs and langerin 2 DCs (Lang 2 DCs), in the generation of local CTL responses following intravaginal immunization with an immunogen comprising CTB conjugated to OVA (CTB-OVA).
Materials and Methods

Mice
Female 6-to 8-wk-old C57BL/6 mice were from Charles River Laboratories (L'Arbresle, France). Lang-EGFP and Lang-DTR-EGFP transgenic mice were described elsewhere (19) . LC ablation into Lang-EGFP/Lang-DTR-EGFP mice was accomplished by i.p. injections of diphtheria toxin (DT; 1mg) (List Biological Laboratories, Campbell, CA) 4 and 1 d prior to immunization. OT-I and OT-II transgenic mice were used as the source of OVAspecific CD4 and CD8 T cells. All mice were maintained in pathogen-free conditions, and studies were approved by our institutional review committee.
Reagents
Cholera toxin (CT) was obtained from List Biological Laboratories. Recombinant CTB was from SBL Vaccines (Uppsala, Sweden). Albumin Chicken Egg Grade VII (OVA) was from Sigma-Aldrich (St. Louis, MO). OVA was conjugated to CTB, and conjugates were checked by ELISA, as described earlier (22, 23) . OVA 257-264 (SIINFEKL) and OVA 323-339 (IS-QAVHAAHAEINEAGR) peptides were from NeoMPS (Strasbourg, France). LPS contamination of preparations was ,0.12 ng/ml (Limulus amebocyte test Pyrogen Plus; Cambrex BioWhittaker, East Rutherford, NJ).
Immunizations
Depoprovera-treated C57BL/6 or Lang-EGFP/Lang-DTR-EGFP mice (depleted or not in LCs by DT injections) were immunized vaginally at days 0, 14, and 21 with 20 ml CTB-OVA (40 mg), with CT (1 mg) or OVA (20 mg) , and used to analyze ex vivo effector TCR-OVA CD8 T cells and to monitor in vivo cytolysis. In vivo cytolysis was conducted as previously described after injection of fluorescent targets (9, 24) . For Ag presentation experiments, Lang-EGFP mice received a vaginal 20-ml dose of Ag or a 5-ml dose of Ag under the tongue (sublingual immunization). Organs (vagina, ILNs, or submandibular lymph nodes [SMLNs] ) were collected at time points between 6 and 72 h postimmunization.
Preparation of vaginal cell suspensions from epithelium and lamina propria
Vaginas were excised carefully to avoid any contamination with outer skin. Vaginal epithelial and lamina propria tissues were mechanically separated after overnight incubation at 4˚C in dispase II (Roche Diagnostic Systems, Somerville, NJ) and cells dispersed after collagenase/dispase treatment (Roche Diagnostics) in the presence of DNase I (Roche Diagnostics).
Flow cytometry analysis and sortings
Low-density DC-enriched suspensions from ILNs or SMLNs from C57BL/6 or Lang-EGF mice were prepared onto an optiprep gradient as previously described (25, 26) . Phenotypic analysis or DC sortings were performed after multiparametric stainings with PE-anti-MHC class II (MHCII) (clone 2G9), PerCP-anti-CD8a (clone 53-6-7), Pe-Cy7-anti-CD11c (clone HL3), APCCy7-anti-CD11b (clone M1/70), APC-anti-CD45RB (B220) (clone RA3-6B2), or biotin-mPDCA (Miltenyi Biotec, Auburn, CA), revealed with APCstreptavidin and Alexa488-anti-langerin (clone 923B7; Dendritics, Lyon, France) (intracellular staining onto DC preparations from C57BL/6 mice only, according to the manufacturer's instructions). Vaginal intraepithelial and lamina propria DCs were analyzed using Alexa488-anti-langerin, PEanti-MHCII, PerCP-anti-CD11b, Pe-Cy7-anti-CD11c, APC-Cy7-anti-CD45 (clone 30-F11), APC-anti-Gr1 (clone RB6-8C5) or biotin-anti-CD80 (clone 16-10A1), biotin-anti-CD86 (clone GL1), anti-macrophage biotin-F4/80 (clone C1.A3-1; Caltag Laboratories, Burlingame, CA), biotin-anti-CD205 (clone NLDC-145; Cedarlane Laboratories, Hornby, Ontario, Canada), and biotin-anti-CD24 (clone M1/69), revealed with APC-streptavidin. For T cell analysis (either DC-primed T cells or cell suspensions from Lang-DTR-EGFP immunized mice), cell suspensions from cultures were stained with APC-Cy7-anti-CD45 (clone 30-F11), FITC-anti-CD3 (clone, PECy7-anti-CD8a (clone 53-6-7), PE-conjugated-H-2Kb/SIINFEKL pentamer (ProImmune, Oxford, U.K.), and PerCP-anti-MHCII (clone 2G9 
Ex vivo presentation assays
Sorted DC subsets were cultured at concentrations between 2.5 3 10 3 and 10 3 10 3 DCs, with 10 5 CFSE-labeled naive OT-I and OT-II T cells for 4 d in flat-bottom 96-well plates without exogenous peptides. CFSE dilution was measured by flow cytometry. Controls in which T cells and DC subsets were preincubated with OVA peptides in vitro were performed to check the functionality of DC subsets after isolation. Naive CFSE-labeled OT-I and OT-II T cells were prepared from lymph nodes, as previously described (9) .
Secondary cultures and cytokine assays
After the priming step, 10 4 DC-primed T cells were stimulated with OVApulsed splenic APCs (5 3 10
3 ) for 3 d in round-bottom 96-well plates, and supernatants were collected and assayed for IFN-g, IL-10, IL-17A, TNF-a, and IL-4, using mouse cytometric bead array kits (BD Biosciences) according to the manufacturer's recommendations. Cytokine profiles (IL-17A, IFN-g) were also evaluated by intracellular staining. Phorbol 12-myristate 13-acetate (200 ng/ml; Sigma-Aldrich), ionomycin (1 mg/ml; Sigma-Aldrich), and GolgiPlug (BD Biosciences) were added in the last 4 h of secondary cultures. Cells were then collected and extra-and intracellular stainings done as described above in the flow cytometry analysis and sortings discussion.
Effector T cell analysis
Organs (vagina, ILNs, spleen) from DT-treated and nontreated immunized Lang-DTR-EGFP mice were collected 7 d after the last immunization. Spleen and ILN cells were dispersed mechanically. Vaginas were excised carefully, and vaginal cells were mechanically dispersed after collagenase A digestion (Roche Diagnostics) of vaginal fine pieces for 45 min at 37˚C in the presence of DNAse I (Roche Diagnostics). Cell suspensions were freed from erythrocytes by treatment with ammonium chloride. Cell suspensions were counted and directly stained, as described in the flow cytometry discussion, above, to determine the frequency and absolute numbers of TCR-OVA + CD8 + T cells. In parallel, 5 3 10 5 total cells were stimulated with phorbol 12-myristate 13-acetate (200 ng/ml; Sigma-Aldrich) and ionomycin (1 mg/ml; Sigma-Aldrich) in the presence of GolgiPlug (BD Biosciences) for 4 h in round-bottom 96-well plates before analysis of IFN-g and granzyme B expression by intracellular staining to determine the frequency of effector CD8 T cells.
Statistical analysis
Groups were compared using a one-way variance analysis and a Tukey test. A p value , 0.05 was considered significant. All statistical calculations were computed with Sigma Stat software (SPSS, Chicago, IL).
Results
Vagina-derived DCs are involved in CD8 T cell responses after intravaginal immunization with a subunit Ag
Using different OVA Ag formulations administered by the vaginal route in C57BL/6 mice, we demonstrated that CTB-OVA induced moderate OVA-specific CTLs (30% OVA-specific cytolysis) in ILNs, which drain the genital and rectal mucosae, but not the skin. The administration of CTB-OVA in the presence of CT, a strong mucosal adjuvant, potentiated the OVA-specific cytotoxic activity (90% OVA-specific cytolysis), whereas OVA used alone at the same concentration or coadministered with CT was inefficient (Fig. 1A ) (9) . Complementary to this, we previously demonstrated that the immunogen delivery properties of CTB were explained by its mucoadhesive properties toward cells expressing the ganglioside GM1 (all nucleated cells, including mucosal epithelial cells) and its ability to deliver immunogens in the MHC class I pathway (9) .
We further examined which type or types of APCs were involved in the priming of CD8 T cells after intravaginal immunization. CD11c + DCs and CD11c 2 MHCII + APCs (non-DC APCs) were isolated from the ILNs of mice at different time points between 6 h and 72 h after intravaginal immunization with CTB-OVA+CT or OVA alone used as control. Enriched APCs were cultured with naive OVA-specific CD8 T cells. Preliminary studies indicated that good proliferative responses were induced 36 h after immunization (data not shown) (9) . As illustrated in Fig. 1B , DCs isolated from mice 36 h after intravaginal immunization with CTB-OVA+CT were highly efficient in inducing the specific proliferation of CD8 + T cells, as measured by CFSE dilution (60% proliferating OT-I T cells), whereas non-DC APCs were not (4% proliferating OT-I T cells). The rate of proliferation induced by ILN DCs was dependent on the T/DC ratio (Fig. 1C) .
We then evaluated whether the different DC subsets present in the ILNs were able to present the Ag acquired in vivo after intravaginal immunization. In the mouse, DC subtypes express the a N integrin CD11c and the MHCII molecule (27) . On the basis of the phenotypical properties assigned to tissue-derived and bloodderived DCs of peripheral lymph nodes in different studies using the differential expression of MHCII and CD11c, we identified three major DC subsets in the ILNs: CD11c int MHCII high DCs corresponding to mucosa-derived DCs (Muc-DCs), CD11c high MHCII int corresponding to conventional blood-derived DCs (cDCs), and CD11c int MHCII int DCs, which also express the mPDCA marker specific to plasmacytoid DCs (pDCs) (Fig. 1D , left panel; data not shown). Muc-DCs, obtained from mice immunized 36 h earlier with CTB-OVA+CT given by the vaginal route, but not the same cells from mice immunized with OVA alone, were able to induce the proliferation of CD8 OT-I T cells (66% versus 0.8% proliferating T cells, respectively) (Fig. 1D , right panel). Neither cDCs nor pDCs were able to present the CD8 OVA epitope to OT-I T cells, as shown by the absence of proliferation (Fig. 1D, right panel) . Nevertheless, sorted cDCs and pDCs are functional after isolation, as they are able to prime OT-I T cells when pulsed in vitro with the OVA epitope (SIINFEKL) (data not shown). This strongly suggests that the Ag had been taken up locally by mucosal DCs and carried into draining ILNs. Furthermore, DC subsets isolated from ILNs at shorter time points (6 and 12 h) postimmunization were not able to present the Ag administered by the vaginal route, which sustains this conclusion (data not shown). Together, these results rule out the possibility that the topically-applied Ag had diffused alone through lymphatic vessels. Alternatively, we cannot exclude that the Ag may have diffused, but not in an immunologically relevant fashion.
Intravaginal immunization induces the migration of vaginal LCs and Lang 2 DCs in ILNs
To identify the nature of the Muc-DCs involved in the priming of CD8 and CD4 T cells, we analyzed the phenotype of DC subsets present in the vaginal mucosa and in the ILNs before and after Ag administration, using classical markers expressed by DC subsets of the skin (14, 28, 29) . We used Lang-EGFP mice, in which langerin + DCs, including LCs, express the EGFP (19) . Cell suspensions from vaginal epithelium and lamina propria were analyzed by flow cytometry for their content in CD11c + MHCII + DCs expressing langerin. To this end, we compared langerin expression in C57BL/6 mice, using a monoclonal anti-langerin Ab, and in Lang-EGFP mice, measuring EGFP expression. Only a small DC subset expresses langerin, which corresponds to ∼1-3% of CD11c + MHCII + DCs, accounting for ∼1% of total epithelial cell suspensions from progesterone-treated mice ( Fig. 2A, upper panel,  Supplemental Fig. 1 ). This intraepithelial population represents a higher percentage in Lang-EGFP mice ( Fig. 2A, upper panel) . We also analyzed the frequency of LCs in the vaginal epithelium in the absence of progesterone treatment. We observed that LC frequency in nontreated mice represented 12-20% of intraepithelial DCs, corresponding to only a 2-to 3-fold increase in LC numbers per vagina, compared with progesterone-treated mice ( Fig. 2A, lower panel) . We then phenotypically characterized the DCs present in the vaginal mucosa of progesterone-treated C57BL/6 mice, using intracellular langerin staining (Fig. 2B, 2C) . Vaginal LCs represent a rare but homogeneous population of mucoepithelial LCs expressing high levels of CD205 and CD24, and intermediate levels of costimulatory molecules CD80 and CD86 (Fig. 2B, right histograms) . The majority of intraepithelial DCs do not express langerin (Lang 2 DCs). They constitute a heterogeneous population, as shown by variable expression of F4/80 and CD24 according to previous observations (Fig. 2B , left histograms; Refs. 11-13). LCs or langerin + DCs are undetectable in the vaginal lamina propria, which contains a subset of DCs quite similar to dermal DCs (Fig. 2C, Supplemental Fig. 2) . Furthermore, vaginal DC subsets from the epithelium and the lamina propria are negative for CD8a, CD45RB/B220, and NK/ DX5 markers (data not shown).
We also observed a transient increase in Lang 2 DC and LC numbers in the vaginal epithelium 6 h after intravaginal administration of CTB-OVA+CT, demonstrating that both populations were able to respond to this immunostimulatory Ag (Fig. 2D) . We then analyzed the langerin expression by the DC subsets present in ILNs, and we found that ILNs contained only a very small subset of mucosa-derived LCs, accounting for 3% Muc-DCs (Fig. 3A) . Furthermore, these LCs did not express CD8a, which is consistent with their mucosal origin. Their low percentage among Muc-DCs (3%) is in accordance with the low proportion of LCs in the genital mucosa ( Figs. 2A, 3A) . Interestingly, 36 h after intravaginal administration of CTB-OVA+CT, we observed in the ILNs 6-fold and 3-fold increases in the frequencies of mucosa-derived Lang 2 DC and LC subsets, respectively, whereas cDC and pDC frequencies were not significantly modified ( Fig. 3B ; data not shown). The increase in DC frequency within ILNs was accompanied by their maturation, as indicated by a slight upregulation of costimulatory molecules CD80 and CD86, suggesting that these cells have recently emigrated from the mucosa after activation (Fig. 3C) DCs to prime OVA-specific CD8 and CD4 T cells. For this purpose, mucosa-derived Lang 2 DC and LC subsets were isolated by cell sorting from DC-enriched low-density fractions from ILNs of Lang-EGFP mice 36 h after intravaginal administration of CTB-OVA+CT. Mucosa-derived Lang 2 DC and LC subsets were sorted with a purity of 97% and 98%, respectively (Fig. 4A) . Lang 2 DCs and LCs were able to induce the proliferation of OVAspecific OT-I T cells (Fig. 4B, left panels) , which demonstrates that both subsets are capable of capturing the CTB-OVA Ag in the vaginal mucosa, processing it, and presenting pertinent epitopes to specific CD8 T cells. These results are consistent with the mature phenotype of these DC subsets, as observed by flow cytometry (Fig. 3C) . Nevertheless, on a per cell number basis, LCs were less efficient than mucosa-derived Lang 2 DCs for inducing CD8 T cell proliferation (69% proliferating OT-I T cells versus 93% proliferating OT-I T cells). Furthermore, LCs failed to induce proliferation of CD4 OT-II T cells, in contrast to mucosa-derived Lang 2 DCs (Fig. 4B, right panels) .
Mucosa-derived LCs and Lang
2 DCs from the sublingual mucosa have Ag-presenting properties comparable to those of vagina-derived DCs
We then asked whether Muc-DCs from another pluristratified mucosa, the sublingual mucosa, had similar ability to present Agderived epitopes to specific CD4 and CD8 T cells after local immunization. We chose the sublingual mucosa because it constitutes an interesting site of mucosal immunization, and because, similarly to the vaginal epithelium, the sublingual epithelium contains Lang 2 DCs and LCs but in different percentages (68% Lang 2 DCs versus 32% LCs) (Supplemental Fig. 3 ) (30). Mucosaderived Lang 2 DCs and LCs, cDCs, and pDCs were isolated from DC-enriched low-density fractions from draining SMLNs of Lang-EGFP mice at different time points between 12 h and 72 h after sublingual application of CTB-OVA+CT. Preliminary experiments showed that 24 h after sublingual application of CTB- OVA+CT, OVA-specific CD4 and CD8 epitopes were efficiently presented by sorted Muc-DCs but not by cDCs and pDCs (data not shown). At 24 h after immunization, both sublingually-derived Lang 2 DC and LC subsets were able to induce the proliferation of OVA-specific CD8 T cells, demonstrating their ability to capture and process the OVA Ag in vivo (Fig. 5A, left panel) . As observed for vaginal LCs, sublingual LCs, compared with Lang 2 DCs, were inefficient in inducing the proliferation of OVA-specific CD4 T cells (Fig. 5A, right panel) . Nevertheless, sorted LCs were functional, as indicated by their ability to induce strong CD8 and CD4 proliferation in the presence of exogenous OVA (Fig. 5B) . The latter observations further exclude that the sorting strategy employed might have inadvertently affected functions of LCs. Furthermore, the culture of OVA-specific CD8 and CD4 T cells alone (Fig. 5D ) or in the presence of Lang 2 DC and LC subsets isolated from ILNs of control CT-treated mice (Fig. 5C ) did not induce any T cell proliferation, which indicates that the proliferation observed postimmunization with CTB-OVA+CT was Ag specific.
Altogether, our results demonstrate that mucosa-derived Lang (Fig. 4B, upper panel) , and this priming is associated with production of high levels of IFN-g (4700 6 290 pg/ml) but limited amounts of IL-10 (34 6 20 pg/ml) in secondary cultures (Fig. 6A) . In contrast, vagina-derived LCs primed OVA-specific CD8 T cells with moderate proliferative activity (Fig. 4B, lower panel) . Secondary culture supernatants of LC-primed T cells induced around 5-fold lower amounts of IFN-g (1090 6 580 pg/ml) and higher levels of IL-10 (220 6 100 pg/ml) (Fig. 6A) . The IFN-g/IL-10 ratio of T cells primed by Lang 2 DCs was 20-fold higher (IFN-g/IL-10 ratio .100) than the one of T cells primed by mucosa-derived LCs (IFN-g/IL-10 ratio ,5).
We also observed that secondary culture supernatants of LCprimed T cells produced substantial amounts of IL-17A cytokine (485 6 140 pg/ml), contrary to Lang 2 DCs (109 6 60 pg/ml) or control groups (,20 pg/ml) (Fig. 6A) . These results are confirmed by intracellular staining of DC-primed T cells (Fig. 6B) . IFN-g and IL-17A cytokines produced in these secondary cultures are mainly secreted by stimulated DC-primed T cells, not by APCs. No specific IL-10 staining was detected by intracellular staining in these cultures. This can in part be explained by the fact that IL-10 is produced at lower levels by these cultures and by a too small percentage of stimulated T cells to be detected.
In vivo ablation of LCs enhances the generation of genital TCR-OVA CD8 + T cells and CTL responses
We then evaluated the in vivo contribution of vaginal LCs in the generation of TCR-OVA + CD8 + T cells and CTL responses after intravaginal immunization with CTB-OVA+CT, as illustrated in Fig. 7A . For this purpose, we used Lang-EGFP/Lang-DTR-EGFP mice, in which DT injections induced a transient depletion of langerin + cells (16) . One group of mice (n = 6) received two consecutive DT injections at days 4 and 1 before intravaginal immunization, a protocol efficient for inducing a total depletion of vaginal LCs (Fig. 7B) and one that has no significant effect on vaginal Lang 2 DC numbers (Supplemental Table I ). At 1 wk after the third intravaginal immunization, the presence of functional OVA-specific CTLs was determined in ILNs, vaginal mucosa, and spleen in nontreated (2DT) and DT-treated (+DT) mice. The in vivo ablation of LCs did not suppress the generation of vaginal and systemic OVA-specific cytotoxic responses (Fig. 7C) , which is not surprising owing to the high priming potential of Lang 2 DCs after mucosal CTB-OVA in vivo uptake (Figs. 4B, 6 ). Interestingly, the in vivo ablation of vaginal LCs induced a statistically significant increase in cytotoxic activity (34%) in the vagina (Fig. 7C) . Furthermore, we analyzed the frequency and absolute numbers of Ag-specific TCR-OVA + CD8 + T cells after immunization in DT-treated (+DT) and nontreated (2DT) mice. As shown in Fig. 7D for a representative experiment, the frequency of TCR-OVA + CD8 + T cells was increased in the vaginal mucosa of mice immunized in the absence of LCs (+DT), in comparison with nontreated (2DT) mice (29% versus 13% TCR-OVA + CD8 + T cells in vagina). The increased frequency of Agspecific T cells in the absence of LCs is also accompanied by a 3-fold increase in the absolute numbers of TCR-OVA + CD8 + T cells per vagina in DT-treated mice compared with nontreated mice (Vagina, +DT: 14900 6 1500 TCR-OVA + CD8 + T cells versus vagina, 2DT: 4600 6 1500 TCR-OVA + CD8 + T cells) (Fig. 7E) . Interestingly, LC depletion is also associated with an increased frequency of granzyme B + IFN-g + in CD8 T cells in the vaginal mucosa of DT-treated mice (Fig. 7F) . The effect of LC depletion on Ag-specific CD8 T cells is restricted to vaginal effector T cells and has no significant effect on ILN and spleen effector T cells (Fig. 7C-E) .
Altogether, these data suggest that vaginal LCs are endowed with Ag-specific regulatory activities on vaginal effector CD8 T cell responses.
Discussion
We have examined the contribution of vaginal DCs in the generation of CTL responses after intravaginal application of a model Ag. We have identified in the vaginal epithelium a minor DC subset corresponding to epidermal LCs and a major DC subset that does not express langerin (Lang 2 DCs). Our study demonstrates that MucDCs, including LCs and Lang 2 DCs, are involved in the priming of Ag-specific CD8 T cells. Vaginal LCs differentiate CD8 T cells producing IL-10 and IL-17A, whereas vaginal Lang 2 DCs prime IFN-g-producing T cells. Moreover, not only are vaginal LCs dispensable for the generation of intravaginally induced CTL responses but also their in vivo ablation prior to immunization enhances vaginal Ag-specific CD8 T cells and CTL responses, suggesting they have a regulatory activity on these responses. This may be partly explained by their ability to prime CD8 T cells exhibiting a cytokine profile dominated by IL-17A and, to a lesser extent, IL-10.
Regarding the phenotype of vaginal DC subsets, our work confirms the heterogeneity of vaginal DCs, a feature reported first by Parr and Parr (11) and, more recently, by Iwasaki et al. (12, 13) . Our observations further document the existence of two DC subsets in the mouse vaginal epithelium, including LCs and Lang 2 DCs, which contrasts with the situation seen in the skin, in which all epidermal DCs are LCs (Figs. 2, 7 ; Refs. [19] [20] [21] .
Vaginal LCs represent a minor yet homogeneous DC subset expressing levels of langerin comparable to those in skin LCs (Figs.  2, 7 ). This observation contrasts with a recent report by Iijima et al. (13), claiming that VEDCs do not express langerin or express it at very low levels. This discrepancy may be explained by the use of different monoclonal anti-langerin Abs, and of different enzymatic tissue dispersion procedures to prepare vaginal cells, which can affect cell recovery and expression of certain markers. Indeed, different isoforms of langerin are described in the mouse, which can explain different anti-langerin Ab reactivities (31) . Moreover, using Lang-EGFP mice, we confirmed the presence of a minor subset of LCs in the vaginal epithelium ( Fig. 2A) . Furthermore, the observation that we identified higher LC percentages in Lang-EGFP mice than in C57BL/6 mice suggests that the antilangerin Ab we used does not recognize all langerin isoforms. Moreover, vaginal LCs express brightly positive CD24, recently described as a specific LC marker in the epidermis (32) . We also characterized a subset of Lang 2 DCs in the vaginal epithelium, which constitutes a heterogeneous subset with bimodal expression of the macrophage marker F4/80, the CD205 receptor, and the CD24 Ag. This finding suggests that some of these DCs might represent LCs that do not express langerin, as proposed by Iijima et al. (13) . The relationship between this subset and LCs remains to be established.
In the absence of progesterone treatment, a condition in which the vaginal epithelium is thick, we observed a slight increase in LC numbers in the vaginal epithelium, which may be explained by changes in the epithelial architecture. This finding suggests that modifications of hormonal status may influence the distribution and functions of vaginal DC subsets, which requires further investigation. Moreover, it is worth mentioning that Lang 2 DCs and LCs are present in the epithelium of another pluristratified mucosa, the sublingual mucosa (30) (Supplemental Fig. 3 ). The presence of Lang 2 and LCs in mucosal epithelia seems to be a common feature of pluristratified mucosae, contrary to the skin. This observation, along with the absence of Langerin + DCs or migratory Langerin + LCs in the vaginal lamina propria (Fig. 2) , two DC subsets previously described in the skin dermis (16, 17) , emphasizes the particularity of the vaginal mucosa. Altogether, our data and previous reports (11) (12) (13) highlight the DC heterogeneity in mouse vaginal mucosa and the differences between pluristratified mucosae and skin.
We observed that our Ag applied onto a pluristratified epithelium (vagina and sublingual mucosa) is cross-presented to CD8 T cells by Muc-DCs, including Lang 2 DCs and LCs, but not by resident DCs (cDCs and pDCs) (Figs. 4, 5 ). This observation is in accordance with a report (33) (Fig. 6 ). Our observation that LCs are competent in vivo to cross-present CD8 epitopes after Ag uptake in mucosal tissues is consistent with data showing that OVA applied onto skin or expressed by keratinocytes was efficiently cross-presented to CD8 T cells by LCs (34, 35) . Regarding vagina-derived Lang 2 DCs, we and others have demonstrated that this DC subset efficiently presents both CD4 and CD8 epitopes after intravaginal application of different Ags ( Fig. 4 ; Refs. 12, 33). This last DC subset is also characterized by the expression of the integrin CD11b and the absence of the CD8a molecule. Its ability to cross-present CD8 epitopes from tissuederived Ags contrasts with previous data demonstrating that resident splenic CD8 + DCs were equipped to cross-present protein Ag, but not CD11b + DCs (36) . This finding confirms that tissuederived CD11b + DCs are functionally different from splenic CD11b + DCs. Furthermore, the strong priming potential toward IFN-g-producing CD4 and CD8 T cells of Lang 2 DCs, their strategic location in the epithelium in direct contact with the vaginal lumen, suggests that they might play a critical role in induction of protective immunity against vaginal infections by intracellular pathogens. Altogether, our data and other reports reinforce the notion that cross-presentation by different DC subsets is dictated by the site and the type of Ag delivery (injection or topical application), as well as the nature of the Ag (invasive versus noninvasive Ags). In skin, conflicting data regarding the role of epidermal LCs in the promotion or control of immunity, in particular in the induction of contact hypersensitivity (19) (20) (21) , have been initially reported. These discrepancies can be explained by different parameters, including DT-depletion protocols, application sites of Ags (ear skin versus abdominal skin), doses, and nature of the Ags used. Indeed, under defined stimulatory conditions, skin LCs seem to contribute to productive immune responses but are dispensable (37) . In the vaginal environment, vaginal LCs preferentially prime CD8 T cells with potential regulatory/suppressive functions, which is consistent with the increase in T CD8 cytotoxic activity in the vagina of LC-depleted mice (Figs. 6, 7) . Indeed, vaginaderived LCs primed CD8 T cells toward a mixed cytokine profile, dominated by IL-17A and, to a lesser extent, by IL-10 ( Fig. 6) , two cytokines believed to be produced by suppressive CD8 T cells during viral infections (38, 39) . Alternatively, IL-17 produced by Th17 cells has also been described as inhibiting CD8 T cell cytotoxicity (40) . Further studies are needed to definitely establish the role of IL-17-and/or IL-10-producing T cells in the regulation of vaginally induced CTLs.
Following vaginal immunization with a CT-based immunogen, vaginal LCs prime IL-17-producing T cells, contrary to vaginal Lang 2 DCs, which mainly differentiate IFN-g-producing CD4
and CD8 T cells, two T cell profiles known to be induced by CT (Fig. 6 ). This finding indicates that these tissue-derived DCs differentially respond to the same microbial stimulus and may have different intrinsic properties. This is consistent with data demonstrating that human skin migratory LCs are more efficient than dermal DCs in inducing IL-17-producing CD4 T cells in an in vitro allogeneic system (41) . Nevertheless, other mucosal DC subsets, such as intestinal CD11b + DCs, are also noted to elicit IL-17 production (42) . Further studies using different microbial agents are needed to establish whether this property is restricted to mucosal LCs present in pluristratified epithelia.
Our findings support the contention that vaginal LCs prime Agspecific CD8 T cells, which dampen the generation of mucosal CTLs. This study demonstrates that vaginal LCs not only are dispensable for the generation of mucosal CTL responses but also exert a downregulating activity on these responses, by a mechanism that may involve IL-17 and, to a lesser extent, IL-10. This finding has implications for the rational design of vaccines and immunotherapeutic strategies based on tissue-specific targeting of DCs.
